Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System
Blood · 16.05.2024 · 143 (20) · 2099-2105
DOI: 10.1182/blood.2024024166 ↗Kurz gefasst
Leserbrief in der Zeitschrift Blood, erschienen am 16.05.2024. Verfasst von Magdi Elsallab und 7 weiteren Autor:innen. Beteiligte Einrichtung: Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, MA. Hauptthemen laut MEDLINE: Neoplasms, Second Primary, United States Food and Drug Administration, Immunotherapy, Adoptive, Adverse Drug Reaction Reporting Systems. Die Arbeit wurde bisher 165-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Second primary malignancies were reported in 536 of 12 394 (4.3%) adverse event reports following chimeric antigen receptor T-cell therapies in the Food and Drug Administration Adverse Event Reporting System. Myeloid and T-cell neoplasms were disproportionately more frequently reported, warranting further follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, MA.
- Cellular Immunotherapy Program, Mass General Cancer Center, and Department of Medicine, Harvard Medical School, Boston, MA.
- Fred & Pamela Buffett Cancer Center, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE.
- Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE.
- Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
- Department of Medicine, Weill Cornell Medical College, New York, NY.
ORCID-Profile: Magdi Elsallab, Moataz Ellithi, Matthew A Lunning, Christopher D'Angelo, Miguel-Angel Perales, Marcela V Maus
Zitieren
APA
Elsallab, M., Ellithi, M., Lunning, M. A., D'Angelo, C., Ma, J., Perales, M. A., Frigault, M., & Maus, M. V. (2024). Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System. Blood, 143(20), 2099-2105. https://doi.org/10.1182/blood.2024024166
Vancouver
Elsallab M, Ellithi M, Lunning MA, D'Angelo C, Ma J, Perales MA, et al. Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System. Blood. 2024;143(20):2099-2105. doi:10.1182/blood.2024024166
BibTeX
@article{Elsallab2024,
author = {Elsallab, Magdi and Ellithi, Moataz and Lunning, Matthew A and D'Angelo, Christopher and Ma, Jihyun and Perales, Miguel-Angel and Frigault, Matthew and Maus, Marcela V},
title = {Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System},
journal = {Blood},
year = {2024},
volume = {143},
number = {20},
pages = {2099--2105},
doi = {10.1182/blood.2024024166}
}
EUVIMED